AORT

Artivion, Inc.

• Simply Wall St·09/18 08:25

  AMDS Approval Could Be A Big Test For Artivion Stock (AORT)

• TipRanks·09/05 02:10

  Top Artivion Executive Makes Notable Insider Move in Latest Stock Transaction

• Simply Wall St·08/28 09:24

  How Investors Are Reacting To Artivion (AORT) Repricing and the AMDS U.S. Rollout Pivot

• Simply Wall St·08/24 10:29

  Have Artivion Insiders Been Selling Stock?

• TipRanks·08/21 02:10

  Artivion CEO Makes Bold Move With Major Insider Stock Sale

• Simply Wall St·08/19 22:31

  Does Revenue Growth Amid New Losses Reshape The Bull Case For Artivion (AORT)?

• TipRanks·08/19 00:14

  Artivion Earnings Call: Growth Drivers vs. Debt Load

• Dow Jones·08/18 13:47

  Artivion Is Maintained at Buy by Canaccord Genuity

• Dow Jones·08/18 13:47

  Artivion Price Target Raised to $40.00/Share From $39.00 by Canaccord Genuity

• Benzinga·08/18 13:37

  Canaccord Genuity Maintains Buy on Artivion, Raises Price Target to $40

• TipRanks·08/18 11:00

  Artivion price target raised to $40 from $39 at Canaccord

• TipRanks·08/18 02:02

  Artivion Executives Quietly Cash In With Fresh Insider Stock Moves

• The Motley Fool·08/14 00:46

  Artivion (AORT) Q2 2026 Earnings Call Transcript

• TipRanks·08/13 11:25

  Canaccord Genuity Sticks to Its Buy Rating for Artivion (AORT)

• Simply Wall St·08/12 19:28

  Artivion (AORT) Is Up 5.5% After FDA AMDS Approval And Reaffirmed 2026 Revenue Guidance - What's Changed